Slides
Page 1
Investor Presentation January 2026
Page 2
This presentation contains forward-looking statements within the meaning of the Private Securities litigation Reform Act of 1995. Statements in this presentation that are not statements of historical fact are considered forward-looking statements, which are usually identified by the use of words such as “anticipates,” believes,” “continues,” “could,” “estimates,” “expects,” “intends,” “may,” “plans,” “potential,” “predicts,” “ projects,” “seeks,” “should,” “will,” “forecast,” “budget,” and variations of such words or similar expressions. Statements of past performance, efforts or results, about which inferences or assumptions may be made, can also be forward-looking statements and are not indicative of future performance or results. Forward-looking statements are neither forecasts, promises nor guarantees, and are based on the current beliefs of the RxSight, Inc. (“RxSight,” “we” or “us”) management as well as assumptions made by and information currently available to RxSight. Such statements reflect the current views of RxSight with respect to future events and are subject to known and unknown risks, including business, regulatory, economic and competitive risks, uncertainties, contingencies and assumptions about RxSight. Such statements may include, without limitation, statements regarding (i) adoption trends and projections regarding the future volume of cataract surgical procedures and related revenue and the role of premium IOLs therein, (ii) estimates of RxSight’s addressable market opportunity and related growth, in the U.S. and globally, (iii) the efficacy of RxSight’s mechanisms and procedures, (iv) the performance of other premium and conventional IOLs compared to RxSight’s, (v) the number of patients eligible for LAL procedures, (vi) revenue associated with LAL procedures and the premium IOL market, (vii) statements regarding our future financial or business performance, (viii) the timing and success of our development and commercialization of our products, (ix) the continued acceptance of our products in the marketplace and our competitive positioning, (x) 2025 preliminary LDD installed base, LAL units sold and total revenue; (xi) anticipated continued growth based on RxSight adjustable innovation, and (xii) RxSight's plans to enter international markets. This presentation contains estimates, projections and other information concerning our business, our industry and the markets for our products, including data regarding the estimated size of such markets and the incidence of certain medical conditions. We obtained the industry, market and similar data set forth in this presentation from our internal estimates and research and from academic and industry research, publications, surveys and studies conducted by third parties, including governmental agencies. In some cases, we do not expressly refer to the sources from which this data is derived. Information that is based on estimates, forecasts, projections, market research or similar methodologies is subject to risks, uncertainties and actual events or circumstances may differ materially from events and circumstances that are assumed in this information. More details about these and other risks that may impact RxSight’s business are described under the heading “Risk Factors” in Part II, Item 1A of RxSight’s Quarterly Report on Form 10-Q filed with the U.S. Securities and Exchange Commission (“SEC”) on November 5, 2025, and in subsequent filings with the SEC, which are available on the SEC’s website at www.sec.gov. RxSight cautions you not to place undue reliance on any forward-looking statement, which speaks only as of the date hereof. RxSight does not undertake any duty to update any forward-looking statement or other information in this presentation, except to the extent required by law.
Page 3
Transform cataract surgery outcomes via the power of adjustability to personalize vision OUR VISION
Page 4
$225M+ Cash, Cash Equivalents & ST Investments 2,500+ Surgeons Trained ~10% of US Premium IOL Market 1,100+ Ophthalmic Offices With LDDs ~500 Employees 1,100+ Ophthalmic Offices With LDDs ~300K LAL Procedures Since Inception RxSight Today
Page 5
Cataract & Lens Replacement Surgery One of the most common global surgical procedures Natural lens is removed IOL provides focusing power after lens removal Intraocular Lens (IOL) Fixed Premium Intraocular Lenses Key focus for patients, practices and ophthalmic industry for clinical and financial reasons Toric EDOF PC-IOL
Page 6
From Fixed to Adjustable: Rethinking the Patient Journey Fixed Lens Workflow Choose lens and approximate power Perform surgery Outcome Office-based light treatments personalize the LAL to each patient’s visual preferences Choose LAL and approximate power Real-World Patient Experience Drives Outcomes Perform surgery Adjustable Lens Workflow
Page 7
Adjustability is Becoming a Foundation of Premium Outcomes Adjustability Offers: • Targeted refractive accuracy • Customization to patient lifestyle • High patient satisfaction and confidence Quality of vision Adjustability Binocular range of vision
Page 8
LAL eyes have better odds of achieving optimal visual outcomes (absolute MRSE and MRCyl ≤ 0.50 D)1 Other Lenses LAL The Ability to Adjust the Lens After Surgery Delivers Unmatched Refractive Precision 1. Data on file - RxSight Post-Approval Study
Page 9
Growing Data Set and Clinical Consensus 1. RxSight Data on File: PMCS-002 2. 2025 RxSight Customer Survey PREFERENCE 79% would select for their own premium IOL surgery (vs 11% for multifocal and 7% EDOF) 2 QUALITY 90% believe LAL provides highest quality of vision 2 ACCURACY >94% +/- MRSE 1 OUTCOMES >90% 20/25 distance and J2 near without glasses 1 Real world data from over 3,000 eyes 1 LAL Customer Survey
Page 10
Boosting profitability through premium IOL adoption Unify the Care Team Enables both surgeons and optometrists to actively participate in and benefit from the premium IOL segment. Command a Premium Price Patients demonstrate a high willingness to pay for customized quality, supporting a significant price premium over fixed alternatives. Expand the Premium Market Data shows 40% of LAL patients would have otherwise chosen a standard, non- premium lens. 1 Adjustability Drives Superior Practice Economics 1. Haffey & Company 2024 Economic Study of LAL Users Average additional practice net revenue per LAL implanted $2,064 1
Page 11
Historical Trends $14.7 $22.6 $49.0 $89.1 $139.9 $134.5* 2020 2021 2022 2023 2024 2025 Total Revenue (in millions) 4,471 8,328 25,284 54,873 98,055 109,615* 2020 2021 2022 2023 2024 2025 LAL Units 92 206 400 666 971 1,134* 2020 2021 2022 2023 2024 2025 LDD Installed Base * Preliminary unaudited total
Page 12
Expanding Surgeon Access Through Multiple Paths • New LDD placements in additional practices • Incremental surgeons within existing LDD sites • Open-access model extending reach beyond in-office LDDs Utilization Growth (Same-Store Sales) • Increased procedures per trained surgeon • Driven by training, confidence, and patient demand • Focus on both high- and low-volume surgeons Driving Growth Through Utilization Expansion and Surgeon Access
Page 13
Future Innovation Making Personalized Cataract Surgery Faster, Simpler, and More Precise Workflow Efficiency Expanded Capabilities
Page 14
A Large, Underpenetrated Global Premium Opportunity 4X 1X 1. Market Scope 2025 Premium Cataract Surgery Market Report, October 2025 Progress to Date • Team buildout and regulatory Next Steps • Focus on initial target markets • KOL development, early installs Key OUS markets make up >80% of global procedures with growing procedure potential 1
Page 15
Execution & Growth Optionality Structural improvements in commercial execution International opportunity Pipeline opportunities Adjustability Wins Long-Term Market & Platform Strength Large, growing market Large, stable installed base Only adjustable IOL Revenue & Margin Expansion Utilization-led growth Recurring LAL mix improves gross margins Financial Strength Strong balance sheet to fund growth RxSight offers the only Adjustable IOL
Page 16
Thank You